Aptevo Therapeutics (APVO) Research & Development (2016 - 2022)
Historic Research & Development for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $4.7 million.
- Aptevo Therapeutics' Research & Development rose 288.36% to $4.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $17.9 million, marking a year-over-year decrease of 585.45%. This contributed to the annual value of $17.9 million for FY2022, which is 585.45% down from last year.
- As of Q4 2022, Aptevo Therapeutics' Research & Development stood at $4.7 million, which was up 288.36% from $4.5 million recorded in Q3 2022.
- Aptevo Therapeutics' 5-year Research & Development high stood at $9.7 million for Q2 2018, and its period low was $3.9 million during Q2 2022.
- For the 5-year period, Aptevo Therapeutics' Research & Development averaged around $6.1 million, with its median value being $4.9 million (2020).
- As far as peak fluctuations go, Aptevo Therapeutics' Research & Development soared by 4311.18% in 2018, and later plummeted by 4775.58% in 2020.
- Aptevo Therapeutics' Research & Development (Quarter) stood at $8.6 million in 2018, then increased by 9.66% to $9.4 million in 2019, then plummeted by 47.76% to $4.9 million in 2020, then decreased by 7.51% to $4.5 million in 2021, then grew by 2.88% to $4.7 million in 2022.
- Its Research & Development stands at $4.7 million for Q4 2022, versus $4.5 million for Q3 2022 and $3.9 million for Q2 2022.